Sector News

Lupin buys Symbiomix to expand women’s health specialty business

October 12, 2017
Life sciences

Mumbai-based Lupin’s US subsidiary has acquired Symbiomix Therapeutics for $150m in an all-cash deal to expand its branded women’s health specialty business.

Founded in 2012, Symbiomix Therapeutics, which is based in Newark, New Jersey, is focused on developing therapies for gynecologic infections that can have serious health implications.

Through its acquisition, Lupin adds Symbiomix’ lead candidate Solosec (secnidazole) oral granules. Solosec, a 5-nitroimidazole antimicrobial agent, had secured the approval from the US Food and Drug Administration (FDA) for the treatment of bacterial vaginosis (BV) in adult women.

Solosec’s approval in the US was backed by various studies including two key trials in bacterial vaginosis along with an open label safety study which proved efficacy for single-dose of the drug in 2g strength.

According to Lupin, Solose is the first and only single dose oral treatment indicated for bacterial vaginosis, a very common gynecologic infection in the US, annually affecting 21 million women aged between 14 and 49.

Lupin CEO Vinita Gupta said: “We are delighted to complete the acquisition of Symbiomix and its Solosec brand, which immediately expands Lupin’s US women’s health specialty business into the highly-complementary gynecological infection sector.

“This transaction is an important milestone in the evolution of our Specialty business and gives Lupin a new therapeutic to bring to obstetricians and gynecologists to treat a serious health condition they see frequently in their practices.”

Lupin anticipates the commercial launch of Solosec in the US to be in mid-2018. The drug has been given a Qualified Infectious Disease Product (QIDP) designation by the FDA for bacterial vaginosis. With the QIDP, Solosec will be eligible for a minimum of 10 years of exclusivity in the US.

The bacterial vaginosis drug will join Methergine (methylergonovine) tablets, regarded as the anchor of Lupin’s branded women’s health specialty business.

Source: PBR

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend